# Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:

> **NCT04695704** · PHASE3 · TERMINATED · sponsor: **Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina** · enrollment: 86 (actual)

## Conditions studied

- Covid19
- SARS (Disease)

## Interventions

- **DRUG:** Montelukast
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT04695704
- **Lead sponsor:** Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-11
- **Primary completion:** 2023-07-24
- **Final completion:** 2023-08-28
- **Target enrollment:** 86 (ACTUAL)
- **Why stopped:** The incidence of respiratory Long COVID has decreased in the new waves, thus made impossible to achieve the required study sample.
- **Last updated:** 2024-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04695704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04695704, "Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04695704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*